Table of Contents

With over 40% of adults affected by obesity, Zepbound (tirzepatide) is everywhere right now, with millions using it for weight loss. But safety questions are growing just as fast as its popularity.

Reports of nausea, stomach problems, gallbladder complications, and even rare risks during surgery have left many people unsure if it’s worth it. Clinical trials prove it works, but they also reveal side effects that can’t be ignored.

This article breaks down the science behind Zepbound’s safety, what doctors know, what studies show, and what you should watch out for before starting treatment.

Key Takeaways

  • Dual hormone targeting makes Zepbound unique. By activating both GLP-1 and GIP receptors, it goes beyond appetite control and supports sugar regulation and energy use.
  • Side effects are mainly gastrointestinal and usually temporary. Nausea, diarrhea, constipation, and vomiting are the most frequent symptoms, but often improve with dose adjustments and time.
  • Certain risks require caution. Thyroid cancer history, pancreatitis, gallbladder disease, and eye complications mean some patients may not be suitable for treatment.
  • Slow dose increases, hydration, balanced meals, and open communication with doctors help reduce risks.
  • Medication safety also depends on authenticity. Only FDA-approved pens from licensed pharmacies should be used to avoid dangers from compounded or counterfeit products.

How does Zepbound work?

Zepbound (tirzepatide) is a once-weekly injection that activates two gut-hormone receptors, GLP-1 and GIP. These hormones normally surge after you eat.

Here’s what happens when you use it:

  • Tames your appetite – Zepbound sends signals to your brain that make you feel full faster and reduce cravings, so you naturally eat less.
  • Slows your stomach down – Food leaves your stomach more slowly, which keeps you satisfied longer after meals.
  • Supports your pancreas – When blood sugar is high, it helps your body release more insulin and reduce glucagon, which together keep sugar levels in check.
  • Improves how your body uses energy – Over time, it makes your cells more responsive to insulin, which helps lower blood sugar and supports fat loss.

Because you’re eating less, feeling full longer, and your body is handling sugar more efficiently, the extra pounds start coming off gradually.

What is Zepbound used for?

Hand holding a Zepbound pen

Zepbound is approved for adults who have obesity or are overweight with at least one weight-related condition, such as:

    • type 2 diabetes
    • high blood pressure
    • high cholesterol

When compared to semaglutide, a 2024 study showed that people taking tirzepatide were more likely to lose weight. On average, participants on tirzepatide lost 15.3% of their body weight, while those on semaglutide lost 8.3%.

Another real-world study followed 945 adults with overweight or obesity for six months. In this group, those on tirzepatide lost an average of 6.6 kg (14.6 lbs), while those on semaglutide lost about 3.1 kg (6.8 lbs). More patients on tirzepatide also reached 10% and 15% loss milestones. Among participants without type 2 diabetes, the gap remained, with tirzepatide leading to a 7.0% reduction compared to 3.4% with semaglutide.

In addition, Zepbound has recently been approved for use in treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. By reducing fat around the neck and upper airway tissues, it can lessen airway obstruction during sleep.

In the SURMOUNT-OSA trial, Zepbound cut breathing interruptions by about 25-29 events per hour, compared with only 5-6 fewer with placebo. After a year, 42% of patients on Zepbound alone and 50% on Zepbound with PAP therapy improved to mild or no OSA, versus just 14-16% on placebo.

Participants also lost a significant amount of weight, about 45-50 lbs or 18-20% of body weight, while those on placebo lost only 4-6 lbs.

Is Zepbound safe?

Female doctor measuring waist of overweight patient using tape measure.

Most adults are able to use Zepbound safely, particularly when the dose is raised slowly over time. Side effects of Zepbound tend to involve the stomach or intestines, and these often improve as your body adjusts.

That said, there are important safety concerns that need careful monitoring.

1. Thyroid warning

Animal studies showed that GLP-1 medicines such as tirzepatide caused thyroid C-cell tumors in rodents, but it is not known if this happens in humans. For safety, Zepbound should not be prescribed to people who have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).

The FDA advises that patients be counseled about possible warning signs. These include:

    • a lump in the neck
    • ongoing hoarseness
    • difficulty swallowing
    • trouble breathing

Anyone with a history of MTC or MEN2 should avoid Zepbound or tirzepatide. If you develop new swelling or changes in the neck, or persistent throat symptoms, stop using the medication and contact your healthcare provider right away.

2. Pancreatitis

A large study published in 2023 reported that tirzepatide did not significantly increase the risk of pancreatitis compared with other treatments or with placebo. Still, individual cases of acute pancreatitis have been seen in people taking the drug.

One report described a 64-year-old woman with no clear risk factors who developed severe, necrotizing pancreatitis soon after starting tirzepatide. Unfortunately, she did not survive.

If you’ve ever had pancreatitis, tell your doctor before beginning Zepbound. If you notice sudden, intense abdominal pain that spreads to the back, along with vomiting, stop using the medication and get medical help immediately.

3. Gallbladder and biliary disease

Research has shown that people taking tirzepatide were almost twice as likely to develop problems with the gallbladder or bile ducts compared with those on placebo or basal insulin. When individual conditions such as gallstones, gallbladder inflammation, or bile duct disease were analyzed separately, the differences were not statistically significant.

If you notice new pain on the right side of your abdomen, fever, yellowing of the skin or eyes, or unusually pale stools, contact your clinician. They may recommend an ultrasound to check for gallstones or other gallbladder concerns.

4. Stomach, bowel, and anesthesia concerns

Gastroenterologist consultation, treatment of stomach diseases and ulcers.

Tirzepatide slows the emptying of the stomach, which makes many people feel full more quickly and reduces appetite. This effect also explains why digestive side effects are so common. In clinical studies:

    • nausea was reported by about 25-29% of participants
    • diarrhea by 19-23%
    • vomiting by 8-13%
    • constipation by 11-17%

Most of these issues were mild to moderate, appeared mainly during dose increases, and often improved as treatment continued. Only a small number of people chose to stop the medication because of these symptoms.

There is also an important precaution with surgery. Rare cases of pulmonary aspiration, when stomach contents move into the lungs during anesthesia, have been reported in people taking GLP-1 drugs.

If you are scheduled for a procedure, let your surgeon and anesthesiologist know you are using Zepbound so they can take the necessary safety steps.

5. Kidney safety

Vomiting or diarrhea can sometimes lead to dehydration, which in turn may cause sudden kidney injury. In rare cases, dialysis has been required.

On the other hand, studies suggest that tirzepatide may support kidney health over the long term by improving blood sugar control and lowering albumin levels in the urine. Both outcomes are possible.

Make sure you stay well-hydrated, especially if stomach upset occurs. Contact your doctor if you cannot keep fluids down, and ask whether you should have kidney function tests after a bout of severe vomiting or diarrhea.

6. Eye safety

Fast drops in blood sugar can briefly worsen diabetic retinopathy. Because of this, the tirzepatide label recommends close eye monitoring if you already have eye disease.

Book a retinal exam if you have diabetes and have not had one in the past year. If you already have retinopathy, tell your eye doctor when you start Zepbound so they can set follow-up visits. Report new floaters, flashes, blurring, or dark spots without delay.

7. Low blood sugar and drug combinations

Zepbound rarely causes low blood sugar, but the risk increases when combined with insulin or sulfonylureas.

Work with your doctor on adjusting insulin or sulfonylurea doses before starting Zepbound. Carry fast-acting carbohydrates and know the signs of low blood sugar, such as sweating, shaking, or confusion.

8. Pregnancy, breastfeeding, and family planning

There is not enough research yet to confirm whether tirzepatide is safe during pregnancy. In animal studies, the medicine caused harm to developing offspring, so doctors recommend avoiding it unless the potential benefit clearly outweighs the risk.

It is also unknown if tirzepatide is safe to use while breastfeeding, since studies in nursing mothers have not been done. For this reason, people who plan to become pregnant are usually advised to stop tirzepatide well in advance. If you are preparing for pregnancy, talk with your doctor about the safest timing for discontinuation.

Another point to consider is birth control. Zepbound can reduce the effectiveness of oral contraceptive pills. If you use them, you should either switch to a non-oral option or use a backup method such as condoms for 4 weeks after starting Zepbound and for 4 weeks after each dose increase.

Practical habits for safer Zepbound use

With some mindful steps, you can make your Zepbound treatment safer and more effective.

  • Start low and increase slowly – Treatment usually begins with 2.5 mg once a week for the first four weeks. The dose is then raised step by step, waiting at least four weeks between changes. This gradual approach lowers the chance of stomach problems.
  • Support your body during dose changes – Hydration and balanced meals are especially important when the dose goes up. Focus on lean protein and fiber in small portions. Avoid carbonated drinks and heavy, greasy meals, which can make nausea worse. If symptoms continue, it is safer to stay on the current dose before increasing again.
  • Tell your surgical team – Since tirzepatide can increase the risk of aspiration under anesthesia, always let your surgeon and anesthesiologist know you are using it before any procedure.
  • Protect your kidneys when sick – Vomiting or diarrhea may cause dehydration, which can strain the kidneys. Try to sip oral rehydration solutions. If you cannot keep fluids down, call your doctor. Ask whether you should pause other kidney-stressing medicines and whether blood tests are needed after severe illness.
  • Watch for gallbladder concerns – Pain in the upper right abdomen, fever, or yellowing of the skin or eyes can point to gallbladder problems such as gallstones. Rapid weight loss can raise this risk, so report these symptoms quickly.
  • Schedule eye exams if you have diabetes – When blood sugar improves quickly, eye disease can sometimes worsen for a short time. If you already have retinopathy, closer follow-up with your eye specialist is important.
  • Adjust other diabetes medicines if needed – Zepbound on its own rarely causes low blood sugar. However, combining it with insulin or sulfonylureas can increase the risk. Your doctor may adjust those doses when you start.
  • Use only approved medication – The FDA has warned against compounded or counterfeit GLP-1 products. Make sure you are using genuine Zepbound pens obtained from licensed and trusted sources.

Final Thoughts

Zepbound works by lowering appetite, slowing digestion, improving insulin response, and helping the body manage sugar more effectively. It is approved for weight loss in adults with obesity or overweight and has also shown benefits for obstructive sleep apnea.

However, safety concerns remain. Risks include thyroid tumors in those with a family history of MTC or MEN2, pancreatitis, gallbladder problems, kidney strain from dehydration, and worsening eye disease in people with diabetes. Digestive issues are common but usually improve with gradual dose increases.

Safe use requires careful monitoring, dose adjustments, hydration, and coordination with your healthcare team. When used properly, Zepbound can be an effective long-term treatment for weight and metabolic health.

Related Articles

Frequently Asked Questions

There’s no definitive answer because no large, long-term safety trial directly compares Zepbound and Ozempic. In diabetes trials, tirzepatide and semaglutide had similar types of adverse events (mostly gastrointestinal), though tirzepatide sometimes had higher rates of nausea. Safety depends more on individual risk profiles and contraindications than on one drug being categorically safer.

Head-to-head safety comparisons in obesity are limited. In one trial, Zepbound outperformed Wegovy in weight loss, but adverse effects remained mainly gastrointestinal in both groups. The difference in safety is likely modest, and suitability depends on individual risks and tolerability.

Long-term safety data are still emerging. The SURMOUNT-4 trial ran up to 88 weeks and reported no new safety signals beyond those seen earlier. However, the full lifetime risk (e.g. for pancreatitis, gallbladder disease, thyroid effects) remains under observation.

Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). It should be used cautiously or avoided in pregnancy (safety not established), known hypersensitivity to the drug, and in patients with severe gastrointestinal disease or a history of pancreatitis.

In clinical trials, hair loss (alopecia) happened in up to 5% of patients treated with Zepbound. If hair loss occurs with Zepbound, maintain adequate protein intake, ensure balanced nutrition, and discuss supplements such as biotin or iron with your doctor if deficiencies are suspected.

Yes, many clinical guidelines and specialists regard tirzepatide (Zepbound) as a leading pharmacologic option for obesity when lifestyle therapies are insufficient. That said, whether a specific doctor recommends it depends on patient factors, such as comorbidities, cost, tolerability, and contraindications.

Overeating while taking Zepbound can cause nausea, stomach upset, or even vomiting because the drug slows digestion. It won’t completely cancel out the medicine’s effect, but eating too much regularly can reduce its benefits and make it harder to lose weight.

Sources

Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. https://doi.org/10.1001/jamainternmed.2024.2525

Trinh, H., Donovan, A., & McAdam?Marx, C. (2025). Real?world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting. Diabetes Obesity and Metabolism. https://doi.org/10.1111/dom.16343

Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205. https://doi.org/10.1056/nejmoa2404881

Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1214334

Grennan, K., Borg, C., Meneley, A., Janitz, T., Shuman, M., & Venegas, C. (2025). Fatal, fulminant, necrotizing pancreatitis associated with recent tirzepatide initiation. JCEM Case Reports, 3(6). https://doi.org/10.1210/jcemcr/luaf087

Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1214334

Bosch, C., Carriazo, S., Soler, M. J., Ortiz, A., & Fernandez-Fernandez, B. (2022). Tirzepatide and prevention of chronic kidney disease. Clinical Kidney Journal, 16(5), 797–808. https://doi.org/10.1093/ckj/sfac274

Research, C. F. D. E. A. (2025, September 25). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food And Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss